

PHARMACEUTICAL 2023











Merck & Co. Inc. Rank 52 of 446



The relative strengths and weaknesses of Merck & Co. Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merck & Co. Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 102% points. The greatest weakness of Merck & Co. Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 241%, being 197% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	35,722,000
Cost of Goods Sold	17,411,000
Intangible Assets	41,473,000
Liabilities, Current	24,239,000
Liabilities, Non-Current	0
Other Assets	10,543,000
Other Compr. Net Income	-339,000
Other Expenses	3,763,000
Other Liabilities	0
Other Net Income	0
Other Revenues	59,283,000
Property and Equipment	21,422,000
Research and Development	13,548,000
Selling, General and Administrative Expense	10,042,000

Output Variable	Value in 1000 USD
Assets	109,160,000
Liabilities	24,239,000
Expenses	44,764,000
Revenues	59,283,000
Stockholders Equity	84,921,000
Net Income	14,519,000
Comprehensive Net Income	14,349,500
Economic Capital Ratio	241%

